Dapagliflozin is an SGLT2 inhibitor API used in antidiabetic medications. This white powder is formulated into tablets to manage type 2 diabetes by reducing blood glucose via urine excretion. It also supports heart and kidney health, reducing hospitalization risks. Its high solubility ensures effective oral dosing, improving patient adherence. Dapagliflozin?s stability meets pharmacopeial standards, ensuring reliable performance. As diabetes prevalence rises, Dapagliflozin API drives innovations in metabolic care, offering comprehensive benefits.